Foreign Funds Enter Nationwide Hospital Operation And Management
This article was originally published in PharmAsia News
Hong Kong-listed Golden Meditech has paid HK$830 million to purchase 70 percent of Daopei, China's largest blood disease specialist hospital. At the same time, the firm will gain business licenses and knowledge for national hospital operation and management through its 60 percent acquisition of Jianliang Hospital Management Co., which is the first foreign-owned enterprise qualified to run hospitals nationwide. The deal marks the entry of foreign funds into the sector. The acquisition will allow Golden Meditech to form a complete health care chain and optimize its business network in China's interior region. It will also bring synergy to its health care service, umbilical cord blood hematopoietic stem cell storage and application, as well as medical equipment production and sales. (Click here for more - Chinese Language)
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.